All In Biotech

Drug Trial Radar · NCT01511978

Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome

Inpatient Double-Blind Placebo-Controlled Withdrawal Study of 3,4-Diaminopyridine Base (3,4-DAP) in Subjects With Known Lambert-Eaton Myasthenic Syndrome

Last checked: Nov 20, 2026Latest source record: Jul 11, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

32

Actual

Start

Jan 2012

Primary completion

Feb 2014

Study completion Jul 2015

Sponsor

Lead sponsor
Jacobus PharmaceuticalIndustry
Sponsor type
Industry
First posted
Jan 19, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Hypothesis: 3,4-Diaminopyridine base (3,4-DAP) improves Lambert-Eaton Myasthenic Syndrome (LEMS)-related weakness.

Conditions

  • Lambert-Eaton Myasthenic Syndrome
  • Eaton-Lambert Myasthenic Syndrome

Interventions

  • Continuous 3,4-DAPDrug

    Subjects were maintained on their usual personal dose and schedule of 3,4-DAP base

  • Taper 3,4-DAP to PlaceboDrug

    Subjects were tapered over 3 days from their usual regimen of 3,4-DAP base to placebo with up to an additional 16 hours of placebo before resuming their usual pre-study regimen of 3,4-DAP base

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With 30% or More Deterioration in Triple Timed Up & Go (3TUG) Test, Compared to Time-matched BaselineTime frame: Baseline period (days 0, 1, 2); Randomized treatment period (starting with last dose of day 2, and days 3, 4, 5, and ending with first dose on day 6 when pre-randomization regimen was resumed, or rescue, if indicated sooner)

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • University of California at Davis

    Sacramento, California

  • Indiana University

    Indianapolis, Indiana

  • Duke University

    Durham, North Carolina

  • Oregon Health & Science University

    Portland, Oregon

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Baylor College of Medicine

    Houston, Texas

  • University of Utah

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.